Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20040

STATEMENT	OF CHANGES	S IN BENEFICIAL	OWNERSHIP

OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5

OMB APPROVAL

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Podlesak Dennis				2. Issuer Name and Ticker or Trading Symbol Syndax Pharmaceuticals Inc [SNDX]										ationship o c all applic Directo	able)	g Pers	on(s) to Issi 10% Ow		
(Last) (First) (Middle) C/O SYNDAX PHARMACEUTICALS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 02/08/2018										Officer below)	(give title		Other (s below)	pecify	
35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) WALTHAM MA 02451												X	-/						
(City)	(S	tate)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)			Execution Date,		Code (In				ed (A) o str. 3, 4 a	or 5. Amour Securitie Beneficia Owned F		s For ally (D) following (I) (orm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
							Code	v	Amount	(A) or (D)	Pric	Transaci		ion(s)			mod. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, T	4. Transaction Code (Instr 8)				6. Date Exercisable a Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		Derivative Security		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ownershi Form: ly Direct (D) or Indirec (I) (Instr. 4	Ownership	Beneficial Ownership t (Instr. 4)
					code \	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amour or Number of Shares	er					
Stock Option (Right to Buy)	\$9.63	02/08/2018			A		10,000		(1)	0:	2/08/2028	Common Stock	10,00	00	\$0.00	10,000)	D	

Explanation of Responses:

1. 1/36th of the shares subject to the option shall vest monthly over a three-year period.

Remarks:

/s/ Michael A. Metzger, Attorney-in-Fact 02/12/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.